NASDAQ:CARM Carisma Therapeutics (CARM) Stock Price, News & Analysis $0.0005 0.00 (0.00%) As of 12:25 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsSEC Filings About Carisma Therapeutics Stock (NASDAQ:CARM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Carisma Therapeutics alerts:Sign Up Key Stats Today's Range$0.0005▼$0.000550-Day Range N/A52-Week Range$0.00▼$0.29Volume814 shsAverage Volume56,454 shsMarket Capitalization$20.92 thousandP/E Ratio0.00Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Carisma Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing engineered macrophage and monocyte therapies for cancer and other serious diseases. Its approach is designed to harness the natural ability of these immune cells to locate and interact with disease sites while enhancing their ability to recognize and attack abnormal cells. The company’s technology platform uses genetic engineering to create targeted cell therapies, including chimeric antigen receptor macrophage (CAR-M) candidates. Carisma’s programs are intended to address tumors that may be difficult for conventional immune-cell therapies to reach or treat, including solid tumors. Its lead programs have focused on HER2-targeted therapies, such as CT-0525, an investigational CAR-monocyte therapy being evaluated in clinical development. Carisma Therapeutics was founded through research associated with the University of Pennsylvania and has established operations in Philadelphia. The company became publicly traded on the Nasdaq under the symbol CARM in 2023. Its leadership has included Steven Kelly as chief executive officer. Carisma’s research and development activities are primarily focused on advancing its macrophage-based immunotherapy platform and clinical pipeline.AI Generated. May Contain Errors. Read More Receive CARM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CARM Stock News HeadlinesCarmila: 2025 Annual ResultsFebruary 18, 2026 | businesswire.comCarisma Therapeutics announces Nasdaq delisting, SEC deregistrationDecember 6, 2025 | msn.comA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, and predictions. He argues a simpler approach can work just as well. His free report, The Simple Path To Success With Options, breaks down a repeatable trade setup, common rookie mistakes, and step-by-step blueprints designed to cut through market noise. No complex charts. No guesswork. Just a straightforward setup anyone can learn.October 8 at 1:00 AM | TradeWins (Ad)Carisma Announces Delisting from Nasdaq and SEC DeregistrationDecember 5, 2025 | prnewswire.comCarisma Therapeutics Announces Executive Terminations and Wind-DownOctober 17, 2025 | msn.comCarisma Therapeutics stock plunges after Nasdaq delisting noticeOctober 10, 2025 | investing.comCarisma Therapeutics Faces Nasdaq Delisting and Trading SuspensionOctober 9, 2025 | tipranks.comCarisma Therapeutics Amends Agreement with ModernaSeptember 18, 2025 | tipranks.comSee More Headlines CARM Stock Analysis - Frequently Asked Questions How have CARM shares performed this year? Carisma Therapeutics' stock was trading at $0.0440 on January 1st, 2026. Since then, CARM stock has decreased by 98.9% and is now trading at $0.0005. How were Carisma Therapeutics' earnings last quarter? Carisma Therapeutics Inc. (NASDAQ:CARM) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.05. The business had revenue of $3.65 million for the quarter, compared to analysts' expectations of $2.47 million. When did Carisma Therapeutics IPO? Carisma Therapeutics (CARM) raised $70 million in an initial public offering (IPO) on Thursday, February 6th 2014. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. How do I buy shares of Carisma Therapeutics? Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Carisma Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Carisma Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/13/2025Today10/08/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CARM CIK1485003 Webwww.sesenbio.com Phone617-444-8550Fax617-858-0911Employees20Year Founded2008Profitability EPS (Trailing Twelve Months)$0.73 Trailing P/E Ratio0.00 Forward P/E RatioN/A P/E GrowthN/ANet Income-$60.48 million Net Margins-254.28% Pretax Margin-458.60% Return on EquityN/A Return on Assets-192.17% Debt Debt-to-Equity RatioN/A Current Ratio0.48 Quick Ratio0.48 Sales & Book Value Annual Sales$10.77 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.67) per share Price / Book0.00Miscellaneous Outstanding Shares41,845,000Free Float38,905,000Market Cap$20.92 thousand OptionableNo Data Beta-9.60 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CARM) was last updated on 10/8/2026 by MarketBeat.com Staff. From Our PartnersThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored"The largest market in human history"SpaceX quietly filed paperwork describing what it calls the largest actionable total addressable market in hum...Behind the Markets | Sponsored$169 Private Jet Trick ExposedFor $169, a growing circle of travelers are booking private jets without the wait, the hassle, or the high pri...International Living | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThe Man Who Called Trump’s 2016 Win says, “Beware November 3rd”In 2016, one election model gave Hillary Clinton a 99% chance to win. Jim Rickards went on air and called it f...Paradigm Press | SponsoredYou ignored me once and it cost you... big time.In 2022, Karim Rahemtulla called Rolls-Royce the best value play in market history. Shares have since climbed ...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CARM Stock Alerts